OrsoBio, a leading clinical-level biopharmaceutical company working towards the development of related metabolic disorders and obesity treatments, have showcased the presentation of new preclinical and clinical data at ObesityWeek® 2025 held in Atlanta, Ga, on November 4-7. The company’s leading five abstracts show efficacy, safety and pharmacokinetics (PK) of its streamlined mitochondrial protonophores. The findings emphasise the capability of TLC-1180 and TLC-6740 alone or in combination with glucagon-like peptide-1 (GLP-1) receptor agonists applicable for sustaining and inducing weight loss following incretin therapy footprint.
The mitochondrial protonophores encourage and support weight loss by accelerating energy expenditure, a proven mechanism that contributes to incretin-related therapies. The company is uplifting its portfolio game of protonophores for obesity, led and driven by the liver-focused oral agent TLC-6740. At the ObesityWeek® event the OrsoBio will showcase its Phase 1 data proving its PK and safety of TLC-6740 when incorporated with food, in individuals and acid suppressants with genetic differences that alleviate the functionality of the transporters that arbitrate its hepatic uptake.
The company’s preclinical study of TLC-6740 merges with low-dose semaglutide, creating greater weight loss space in comparison to the maintained metabolic benefits and high-dose semaglutide after a halt in semaglutide in diet-induced obese (DIO) mice.
The MD, PhD, Chief Executive Officer of OrsoBio, Mani Subramanian, said, “We are motivated by these new data elaborating the PK and safety of TLC-6740 and the excellent additive benefits with incorporation in incretin therapy in the preclinical models. These data strengthen our confidence in the efficacy of TLC-6740, both acceptable as monotherapy and in merger with incretins, aligning with our ongoing clinical study.”
The TLC-1180 is a second-generation novel protonophore with systemic distribution and super potency in comparison to TLC-6740. In previous studies, the TLC-1180 bolstered energy expenditure, enhanced glucose control and mitigated body weight in DIO mice. The company will show two additional preclinical studies examining TLC-1180 alone and merged with semaglutide in obese mice and monkeys. Both studies showed superior mitigation and comparison in fat mass and body weight with TLC-1180 monotherapy v/s semaglutide. Including additive benefits from the merger without deteriorating lean mass loss.
The MD, Chief Medical Officer of OrsoBio, Rob Myers, said, “TLC-1180 enhanced insulin sensitivity and promoted a valuable weight loss as monotherapy and involving incretin therapy in non-human primates and rodents.”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
